8-K: Protalix BioTherapeutics Swings to Profit on Elfabrio Sales

Protalix BioTherapeutics reported a net income of $164,000 for Q2 2025, driven by a 16% increase in revenues from selling goods, primarily Elfabrio.

Summary

• Protalix BioTherapeutics reported a net income of approximately $164,000 for the three months ended June 30, 2025, a significant improvement from a net loss of $2.2 million in the same period of 2024.
• Revenues from selling goods increased by 16% to $15.4 million in Q2 2025, up from $13.3 million in Q2 2024.
• The increase in revenues was primarily driven by an $8.0 million increase in sales of Elfabrio to Chiesi, partially offset by decreases in sales to Fiocruz (Brazil) and Pfizer.
• Research and development expenses doubled to $6.0 million in Q2 2025, up from $3.0 million in Q2 2024, mainly due to preparations for the planned Phase 2 clinical trial of PRX-115.
• Selling, general and administrative expenses decreased by 26% to $2.6 million in Q2 2025.
• The company had $33.4 million in cash and cash equivalents and short-term bank deposits as of June 30, 2025.
• Gilad Mamlok has been appointed as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin.
• Protalix was added to the Russell 3000 and Russell 2000 Indexes, effective June 27, 2025.
• The European Medicine Agency (EMA) continues its evaluation of Chiesi's variation submission for the Elfabrio label to include a 2 mg/kg dose administered every four weeks.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant financial turnaround from a net loss to a net income, strong revenue growth driven by Elfabrio sales, and the advancement of a key pipeline asset (PRX-115) into Phase 2 clinical trials. The strategic CFO appointment and inclusion in Russell indexes further bolster confidence, despite expected increases in R&D expenses and ongoing geopolitical risks.

Positives

• Achieved net income of $164,000 in Q2 2025, a significant turnaround from a $2.2 million net loss in Q2 2024.
• Revenues from selling goods increased by 16% to $15.4 million, primarily driven by strong sales of Elfabrio to Chiesi.
• Experienced a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period in 2024.
• Anticipate initiation of a randomized Phase 2 trial for PRX-115 (uncontrolled gout) in the second half of 2025, with first patient enrollment in Q4 2025.
• Appointed a seasoned financial executive, Gilad Mamlok, as the new CFO, indicating a focus on continued growth and financial management.
• Inclusion in the Russell 3000 and Russell 2000 Indexes enhances visibility and liquidity.
• The global Fabry disease market is projected to grow from approximately $2.3 billion currently to $3.2 billion by 2030, providing a significant growth opportunity for Elfabrio.

Negatives

• Sales to Fiocruz (Brazil) decreased by $4.7 million and sales to Pfizer decreased by $1.2 million in Q2 2025 compared to Q2 2024.
• Research and development expenses doubled to $6.0 million in Q2 2025, and are expected to continue to increase as product candidates advance.
• Financial expenses, net, increased to $0.5 million in Q2 2025 from financial income, net, of $0.2 million in Q2 2024, primarily due to exchange rate costs and lower interest income.
• The company recorded a tax expense of $0.5 million in Q2 2025 compared to a tax benefit of $(0.1) million in Q2 2024, impacted by Section 174 of the U.S. Tax Cuts and Jobs Act of 2017.

Risks

• Risks related to the commercialization of Elfabrio, including market acceptance, competition, reimbursement, and regulatory actions, particularly due to the boxed warning in the FDA approval.
• Possible disruption of operations due to the war declared by Israel's security cabinet against the Hamas terrorist organization and other military conflicts, potentially affecting regulatory authorities, suppliers, partners, clinical trial sites, distributors, and customers.
• Risks related to the regulatory approval and commercial success of other product candidates.
• Failure or delay in the commencement or completion of preclinical studies and clinical trials due to factors like slow patient recruitment, unforeseen safety issues, dosing issues, lack of effectiveness, or insufficient funding.
• Delays in the approval or potential rejection of applications filed with the FDA, EMA, or other health regulatory authorities.
• Risks associated with global conditions and developments such as new tariffs, trade restrictions, supply chain challenges, inflationary environment, tight labor market, and banking industry instability.
• Risks related to the ability to raise additional financing in public or private equity or debt markets.
• The risk that clinical trial results will not support safety or efficacy claims, or that product candidates will have undesirable side effects.
• Risks relating to the ability to manage relationships with collaborators, distributors, or partners, including Pfizer and Chiesi.
• Risks relating to the compliance by Fundação Oswaldo Cruz (Fiocruz) with its purchase obligations, which could have a material adverse effect or lead to agreement termination.
• Risk of significant lawsuits, including stockholder litigation.
• Dependence on performance by third-party providers of services and supplies.
• Potential product liability risks and risks of securing adequate insurance coverage.
• The possibility of infringing third-party patents or other intellectual property rights and the uncertainty of obtaining and enforcing intellectual property rights.
• Risks relating to changes in healthcare laws, rules, and regulations.

Future Outlook

The company expects global ordering patterns for Elfabrio to fluctuate quarterly during the early launch phase, but is confident in the long-term growth of the Elfabrio franchise as the launch matures and market share expands. Significant, increasing research and development expenses are anticipated as the company enters a more advanced stage of preclinical and clinical trials for product candidates, specifically with the planned initiation of a randomized Phase 2 trial for PRX-115 in the second half of 2025 and first patient enrollment in the fourth quarter of 2025. The company is also evaluating the impact of new tax legislation (H.R.1) on its consolidated financial statements, which restores current deductibility for domestic research expenditures beginning in 2025.

Management Comments

• "We experienced a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period in 2024, driven primarily by sales of Elfabrio to Chiesi."
• "Chiesi is an ideally suited partner for commercialization of Elfabrio for Fabry disease, which represents a global market of approximately $2.3 billion currently and which is forecasted to grow to $3.2 billion by 2030."
• "As we are still in the early launch phase for Elfabrio, we expect global ordering patterns to fluctuate quarterly while underlying demand characteristics stabilize, the launch matures, and Elfabrio market share expands. We are confident in the growth of our Elfabrio franchise over the long term."
• "We anticipate initiation of a randomized Phase 2 trial in the second half of 2025 and enrollment of the first patient in the fourth quarter of 2025 [for PRX-115]. We look forward to continuing to execute on our strategic plan."
• "Eyal [Rubin] and I have worked closely and collaboratively on Protalix’s transformation. He contributed greatly to strengthening the Company’s capital and preparing us for growth."
• "We are happy to welcome Gilad [Mamlok] to the team and have every confidence that he will play an important role in Protalix’s management as we continue to work toward future growth."

Industry Context

This announcement highlights Protalix's progress in the biopharmaceutical sector, particularly within the rare disease market (Fabry disease) and chronic conditions (gout). The reported revenue growth for Elfabrio, despite being in an early launch phase, indicates positive traction in the competitive Fabry market, which is projected for significant growth. The advancement of PRX-115 into Phase 2 trials positions Protalix to potentially address another substantial unmet medical need in uncontrolled gout. The company's reliance on its proprietary ProCellEx plant cell-based protein expression system offers a unique competitive advantage in protein development and production.

Comparison to Industry Standards

• The filing mentions the global Fabry disease market is approximately $2.3 billion currently and forecasted to grow to $3.2 billion by 2030. While this provides context on market size, the filing does not offer specific comparable companies, projects, or their results to benchmark Elfabrio's performance against direct competitors in the Fabry disease treatment space (e.g., Sanofi's Fabrazyme, Takeda's Replagal, Amicus Therapeutics' Galafold).
• The increase in R&D expenses by 100% for PRX-115's Phase 2 trial preparation is typical for a biopharmaceutical company advancing a pipeline candidate, but no specific industry benchmarks for trial costs or success rates are provided.
• The company's shift from a net loss to a net income is a positive indicator, but without specific peer financial data, a direct comparison of profitability margins or revenue growth rates against similar-sized biopharma companies or those with recently launched rare disease products is not possible from this filing.

Management Changes

Stakeholder Impact

• **Shareholders:** Positive impact due to the company achieving net income, increased revenues, and pipeline advancement, potentially leading to increased shareholder value. Inclusion in Russell indexes may increase liquidity and investor interest.
• **Employees:** The appointment of a new CFO and continued development efforts suggest stability and potential growth opportunities within the company.
• **Customers (Fabry disease patients):** Continued commercialization and potential label expansion for Elfabrio could offer more treatment options and improved dosing flexibility.
• **Partners (Chiesi, Pfizer, Fiocruz):** Strong Elfabrio sales to Chiesi indicate a successful partnership, while decreased sales to Fiocruz and Pfizer might require re-evaluation of those relationships or market dynamics.
• **Creditors:** The repayment of convertible promissory notes in September 2024 reduces debt obligations, potentially improving the company's credit profile.

Next Steps

• Host a conference call and webcast on August 14, 2025, to review financial results and provide a business update.
• Initiate a randomized Phase 2 trial for PRX-115 in the second half of 2025.
• Enroll the first patient in the PRX-115 Phase 2 trial in the fourth quarter of 2025.
• Continue to evaluate the impact of the new U.S. tax reform legislation (H.R.1) on consolidated financial statements.
• Continue to execute on the strategic plan for long-term growth of the Elfabrio franchise.

Key Dates

Recommendation

The company's shift from a net loss to a net income, coupled with a 16% increase in Q2 revenues driven by strong Elfabrio sales, indicates a positive inflection point. The advancement of PRX-115 into Phase 2 trials demonstrates pipeline progress and future growth potential in a growing market. While R&D expenses are increasing and geopolitical risks exist, the overall financial performance and strategic developments suggest a favorable outlook for long-term investors.

Keywords

Biopharmaceutical, Fabry disease, Elfabrio, Gout, PRX-115, ProCellEx, Recombinant proteins, Clinical trials, SEC filing, Financial results, PLX